A Double-blind, Randomized, Placebo-controlled, 4-Period Cross-over Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2019
At a glance
- Drugs JNJ 53718678 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 13 Feb 2019 Planned number of patients changed from 42 to 60.
- 14 Nov 2018 Planned End Date changed from 20 Mar 2020 to 20 Sep 2019.
- 14 Nov 2018 Status changed from not yet recruiting to recruiting.